AstraZeneca to Showcase Breakthrough Respiratory Portfolio at ATS 2024 Conference

AstraZeneca will present new clinical and real-world data at the upcoming American Thoracic Society (ATS) International Conference 2024, held in San Diego. The event will focus on the company’s innovative respiratory portfolio, addressing unmet needs in diseases such as COPD, severe asthma, and EGPA.

Sharon Barr, Executive Vice President of BioPharmaceuticals R&D at AstraZeneca, highlighted the company’s commitment to advancing treatments beyond symptom control towards potential disease modification and cure. The COURSE Phase IIa data on tezepelumab in COPD patients with various profiles will be a key focus of the conference.

Ruud Dobber, Executive Vice President and President of AstraZeneca’s BioPharmaceuticals Business Unit, emphasized the importance of the broad pipeline and inhaled and biologic medicines in transforming respiratory care.

Key presentations at ATS 2024 include insights on Tezspire, investigating inhaled triple therapy Breztri’s impact on cardiopulmonary outcomes, and Fasenra’s role in reducing oral glucocorticoid use in patients with EGPA.

AstraZeneca will also present data on Airsupra, a first-in-class anti-inflammatory rescue therapy for asthma, and early science exploring new modalities for moderate-severe add-on treatments.